Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 18, 2019 16:01 ET | Source: InflaRx N.V.

InflaRx Reports Additional Analysis of the SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa

IFX-1 treatment in high dose group resulted in multiple efficacy signals supporting further development of IFX-1 in HSIFX-1 suppressed C5a levels dose dependently and exhibited a favorable safety...
June 13, 2019 09:00 ET | Source: InflaRx N.V.

InflaRx Treats First Patient in Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum

Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful skin ulcers JENA, Germany, June 13, 2019 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), an innovative...
June 05, 2019 07:49 ET | Source: InflaRx N.V.

InflaRx Announces Top-Line SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa

IFX-1 did not demonstrate a statistically significant dose dependent effect on Hidradenitis Suppurativa Clinical Response (HiSCR) rate at week 16 as primary endpoint IFX-1 treatment achieved a maximum...
May 23, 2019 08:00 ET | Source: InflaRx N.V.

InflaRx Reports First Quarter 2019 Financial & Operating Results

IFX-1: New long-term efficacy data from Phase IIa clinical trial in Hidradenitis Suppurativa presented; approval granted to initiate Phase IIa trial in Canada in Pyoderma Gangraenosum; first patient...
May 14, 2019 08:00 ET | Source: InflaRx N.V.

InflaRx Commences Second Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis with First Patient Treated in Europe

JENA, Germany, May 14, 2019 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today...
March 28, 2019 08:30 ET | Source: InflaRx N.V.

InflaRx Full Year 2018 Financial & Operating Results

$62.9 million (€53.0 million) raised in a follow-on offering to advance clinical programs for IFX-1Start of three Phase II trials for IFX-1 in two serious inflammatory diseasesExpansion of our...
February 27, 2019 08:30 ET | Source: InflaRx N.V.

InflaRx Receives Approval to Initiate Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum

Third autoimmune disease being evaluated with IFX-1 Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful ulcers JENA, Germany, Feb. 27, 2019 (GLOBE NEWSWIRE) --...
February 14, 2019 08:30 ET | Source: InflaRx N.V.

Richard Brudnick to Join InflaRx Board of Directors

JENA, Germany, Feb. 14, 2019 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), an innovative biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
February 06, 2019 07:00 ET | Source: InflaRx N.V.

InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa

Retrospective long-term results from phase IIa trial indicate sustained remission post IFX-1 treatmentBaseline characteristics from ongoing phase IIb SHINE trial in line with expectations; on track...
January 03, 2019 08:30 ET | Source: InflaRx N.V.

InflaRx Continues U.S. Expansion with Addition of New York City Corporate Office and Addition of Management

Jason Marks appointed Chief Legal Officer / General CounselJordan Silverstein appointed Head of Corporate Strategy / Development JENA, Germany and NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) --...